Skip to main content
Clinical Trials/JPRN-UMIN000024327
JPRN-UMIN000024327
Completed
未知

An observational study of serum and cerebrospinal fluid concentrations of osimertinib for the treatment of lung cancer harboring EGFR activating and T790M mutations. - An observational study of serum and cerebrospinal fluid concentrations of osimertinib.

Miyagi Cancer Center0 sites40 target enrollmentOctober 17, 2016
Conditionsung Cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
ung Cancer
Sponsor
Miyagi Cancer Center
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 17, 2016
End Date
March 31, 2021
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Having an evidence of ILD or pulmonary fibrosis complication on chest X\-ray. 2\. With severe complication. 1\)Uncontrollable angina pectoris, myocardial infarction, or heart failure. 2\)Uncontrollable diabetes or hypertension. 3\)Severe infectious disease. 4\)gastrointestinal dysfunction with severe diarrhea. 3\. Impossible to take drugs orally. 4\. Inadequate case considered from drug package insert of osimertinib.

Outcomes

Primary Outcomes

Not specified

Similar Trials